Geode Capital Management, LLC Cyteir Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.84 - $3.13 $40,876 - $45,050	14,393 Added 8.8%	177,930 $540,000
Q3 2023 Nov 13, 2023	BUY	$2.71 - $2.84 $120,608 - $126,394	44,505 Added 37.39%	163,537 $464,000
Q1 2023 May 15, 2023	BUY	$1.47 - $1.84 $2,793 - $3,496	1,900 Added 1.62%	119,032 $216,000
Q4 2022 Feb 13, 2023	BUY	$1.18 - $1.76 $4,134 - $6,167	3,504 Added 3.08%	117,132 $193,000
Q3 2022 Nov 14, 2022	BUY	$1.99 - $4.05 $71,721 - $145,966	36,041 Added 46.45%	113,628 $218,000
Q2 2022 Aug 12, 2022	SELL	$1.62 - $4.4 $240,832 - $654,112	-148,662 Reduced 65.71%	77,587 $231,000
Q1 2022 May 13, 2022	BUY	$3.39 - $10.51 $298,621 - $925,815	88,089 Added 63.76%	226,249 $852,000
Q4 2021 Feb 11, 2022	BUY	$9.83 - $19.21 $425,452 - $831,428	43,281 Added 45.62%	138,160 $1.57 Million
Q3 2021 Nov 12, 2021	BUY	$14.57 - $21.86 $1.15 Million - $1.72 Million	78,599 Added 482.79%	94,879 $1.67 Million
Q2 2021 Aug 13, 2021	BUY	$16.8 - $21.4 $273,504 - $348,392	16,280 New	16,280 $348,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.